Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
Cell Reports|January 21, 2014
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitorsFilip Janku, David S Hong, Siqing Fu, et al.
Investigational New Drugs|September 28, 2020
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancerClinton Yam, Gaiane M Rauch, Tanbin Rahman, et al.
Cancer|March 27, 2018
Development of CNS metastases and survival in patients with inflammatory breast cancerMarc I Uemura, John T French, Kenneth R Hess, et al.
The Oncologist|August 25, 2018
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast CancerReva K Basho, Clinton Yam, Michael Gilcrease, et al.
Clinical Breast Cancer|August 6, 2018
Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution ExperienceRashmi K Murthy, Akshara S Raghavendra, Kenneth R Hess, et al.
European Journal of Radiology|April 22, 2019
Imaging features of triple-negative breast cancers according to androgen receptor statusRosalind P Candelaria, Beatriz E Adrada, Wei Wei, et al.
Investigational New Drugs|January 6, 2019
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II studyClinton Yam, Francisco J Esteva, Miral M Patel, et al.
Ultrasound in Medicine & Biology|March 18, 2022
Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast CancerRosalind P Candelaria, Beatriz E Adrada, Deanna L Lane, et al.
European Journal of Radiology|August 11, 2020
Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patientsRosalind P Candelaria, Beatriz E Adrada, Kenneth Hess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to ChemotherapyToshiaki Iwase, Evan N Cohen, Hui Gao, et al.
Pageof 9